In this analysis, we explore the potential upside for Merck despite its short-term hurdles.

MRK breaks above its 50-day average but near-term headwinds and weak China sales challenge the bullish case.

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers.

Merck’s enlicitide shows promise in lowering LDL-CThe comprehensive CORALreef Phase 3 clinical development program is ongoing and aims to enroll approximately 17,000 patients across several ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here.

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance ...

Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL ...

Jefferson and Oldham county residents will see their MSD bills go up again this year. MSD announced on Tuesday that the board approved a preliminary 4.9% rate increase for the 2026 fiscal year.

U.S. biopharmaceutical giant Merck announced the start of construction for a $1-billion, 470,000-sq-ft biologics center of excellence in Wilmington, Del. Officially called Merck Wilmington Biotech ...

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.

Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that could eventually provide thousands of jobs.